CLVT vs TEM
CLVT: Clarivate provides the essential data, analytics, and insights that empower organizations to accelerate the pace of innovation and protect their intellectual property. TEM: Tempus AI leverages genomic sequencing, clinical data aggregation, and machine learning to deliver precision oncology diagnostics and AI-powered treatment recommendations that guide cancer patient care.
Side-by-side fundamentals
| Metric | CLVT | TEM | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $1.94 | $46.01 | |
| Market cap as of 2026-07-24 | $1.3B | $8.2B | |
| Net margin as of 2026-07-24 | -5.6% | -22.2% | CLVT higher |
| Gross margin as of 2026-07-24 | +66.5% | +63.4% | CLVT higher |
| Operating margin as of 2026-07-24 | +5.0% | -20.6% | CLVT higher |
| ROE as of 2026-07-24 | -2.8% | -70.2% | CLVT higher |
| ROA as of 2026-07-24 | -1.2% | -14.6% | CLVT higher |
| Debt / equity as of 2026-07-24 | 0.89 | 2.96 | CLVT lower |
| Revenue growth (YoY) as of 2026-07-24 | -3.3% | +69.8% | TEM higher |
| Revenue CAGR (3y) SEC XBRL | -2.6% | +58.3% | TEM higher |
| Dividend yield as of 2026-07-24 | +0.0% | n/a | |
| Beta as of 2026-07-24 | 1.38 | 2.89 | |
| 1-year return as of 2026-07-23 close | -54.6% | -29.1% | TEM higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.